Details

Autor(en) / Beteiligte

• Niemantsverdriet, Ellis
• Ottoy, Julie
• Somers, Charisse
• De Roeck, Ellen
• Struyfs, Hanne
• Soetewey, Femke
• Verhaeghe, Jeroen
• Van den Bossche, Tobi
• Van Mossevelde, Sara
• Goeman, Johan
• De Deyn, Peter Paul
• Mariën, Peter
• Versijpt, Jan
• Sleegers, Kristel
• Van Broeckhoven, Christine
• Wyffels, Leonie
• Albert, Adrien
• Ceyssens, Sarah
• Stroobants, Sigrid
• Staelens, Steven
• Bjerke, Maria
• Engelborghs, Sebastiaan

Titel

The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting

Ist Teil von

• Journal of Alzheimer's disease, 2017, Vol.60 (2), p.561

Ort / Verlag

Netherlands

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Evidence suggests that the concordance between amyloid-PET and cerebrospinal fluid (CSF) amyloid-β (Aβ) increases when the CSF Aβ1-42/Aβ1-40 ratio is used as compared to CSF Aβ1-42 levels alone. In order to test this hypothesis, we set up a prospective longitudinal study comparing the concordance between different amyloid biomarkers for Alzheimer's disease (AD) in a clinical setting. Seventy-eight subjects (AD dementia (n = 17), mild cognitive impairment (MCI, n = 48), and cognitively healthy controls (n = 13)) underwent a [18F]Florbetapir ([18F]AV45) PET scan, [18F]FDG PET scan, MRI scan, and an extensive neuropsychological examination. In a large subset (n = 67), a lumbar puncture was performed and AD biomarkers were analyzed (Aβ1-42, Aβ1-40, T-tau, P-tau181). We detected an increased concordance in the visual and quantitative (standardized uptake value ratio (SUVR) and total volume of distribution (VT)) [18F]AV45 PET measures when the CSF Aβ1-42/Aβ1-40 was applied compared to Aβ1-42 alone. CSF biomarkers were stronger associated to [18F]AV45 PET for SUVR values when considering the total brain white matter as reference region instead of cerebellar grey matterConclusions:The concordance between CSF Aβ and [18F]AV45 PET increases when the CSF Aβ1-42/Aβ1-40 ratio is applied. This finding is of most importance for the biomarker-based diagnosis of AD as well as for selection of subjects for clinical trials with potential disease-modifying therapies for AD.